Dr. Meyer will serve as the lead medical oncologist for adult sarcoma patients, and will focus on building the Adult Sarcoma and Connective Tissue Oncology Program. In collaboration with pediatric oncologist David Loeb, M.D., Ph.D., and orthopaedic surgeon Kristy Weber, M.D., Meyer will bring novel therapies to the clinic for sarcoma patients. Meyer received his bachelors and masters degrees in cell and molecular biology from Stanford University. From there, he joined the Medical Scientist Training Program at Baylor College of Medicine and earned his medical degree followed by a doctorate in immunology. Meyer completed his residency at the University of Maryland and served as chief resident in medicine from 2004-2005. Afterward, he joined our fellowship program in medical oncology and has been working in the laboratory of Jonathan Powell, M.D., Ph.D., on projects relating to the characterization of molecular regulatory pathways involved in T-cell activation and energy. As a third-year fellow, Meyer served as the chief fellow for our Training Programs in Hematology and Medical Oncology and he received a Young Investigator Award from the American Society of Clinical Oncology in 2010. Dr. Meyer is rated as an Elite provider by MediFind in the treatment of Rhabdomyosarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Rhabdomyosarcoma, Fibrosarcoma, Osteosarcoma, and Salpingo-Oophorectomy.

Javed Khan is a Hematologist and an Oncologist in Bethesda, Maryland. Dr. Khan is rated as an Elite provider by MediFind in the treatment of Rhabdomyosarcoma. His top areas of expertise are Rhabdomyosarcoma, Adult Soft Tissue Sarcoma, Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, and Angioplasty.

Christine Heske is a Hematologist and an Oncologist in Bethesda, Maryland. Dr. Heske is rated as an Elite provider by MediFind in the treatment of Rhabdomyosarcoma. Her top areas of expertise are Rhabdomyosarcoma, Ewing Sarcoma, Adult Soft Tissue Sarcoma, Osteosarcoma, and Tissue Biopsy.

Adam Levin, MD, joined the Johns Hopkins Department of Orthopaedic Surgery as an assistant professor in orthopaedic oncology. Dr. Levin comes to Johns Hopkins after working as an orthopaedic oncologist at the North Shore/LIJ Health System in New York. He completed his residency in orthopaedic surgery at Long Island Jewish Medical Center, and a fellowship in orthopaedic oncology at the Memorial Sloan-Kettering Cancer Center. Dr. Levin offers care and consultations for adults and children with bone and soft tissue tumors of the pelvis and extremities. He has extensive experience in performing limb-sparing and complex extremity reconstruction surgeries. Dr. Levin has a special interest in surgical palliation and biologic reconstruction. Dr. Levin is a member of the American Academy of Orthopaedic Surgeons and the Musculoskeletal Tumor Society. Dr. Levin is rated as a Distinguished provider by MediFind in the treatment of Rhabdomyosarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Osteosarcoma, Ollier Disease, Hip Replacement, and Osteotomy.

As instructor of oncology and pediatrics, Llosa’s research focus is the immunotherapy of sarcomas. My research focuses on understanding how the immune system interacts with cancer cells from sarcoma tumors. Sarcoma is a type of cancer that can occur in various locations in the body. Sarcoma is the general term for a broad group of cancers that includes tumors that form in the bones and in the soft (also called connective) tissues. Sarcomas affect people of all ages and some, such as Rhabdomyosarcoma, Neuroblastoma, Ewings sarcoma and Osteosarcoma, are more common in children and young adults. Treatments for sarcoma vary depending on tumor type, location and other factors. I concentrate in the immunotherapy of sarcomas. Immunotherapy (also called biologic therapy or biotherapy) is a type of cancer treatment designed to boost the body's natural defenses to fight the cancer. It uses materials either made by the body or in a laboratory to improve, target, or restore immune system function. Immunotherapy works by stopping or slowing the growth of cancer cells, stopping cancer from spreading to other parts of the body, or helping the immune system increase its effectiveness at eliminating cancer cells. There are several types of immunotherapy, including monoclonal antibodies, non-specific immunotherapies, and cancer vaccines. My specific area of interest is the use of drugs that target immune system checkpoints. The immune system has checkpoints to keep itself from attacking other normal cells in the body. Cancer cells sometimes take advantage of these checkpoints to avoid being attacked by the immune system. CTLA-4 and PD-1/PD-L1 are checkpoint molecules found on immune system cells (T cells) that can be blocked with drugs leading to a general raise in the immune system of the patients which helps it attack cancer cells. These types of drugs are currently being given to patients with melanoma (skin cancer), lung cancer and kidney cancer with great success and they have been found to shrink advanced tumors in many people. The best part of the treatment is that many of these tumor responses have been long-lasting so far, and the side effects are generally less serious than when using chemotherapy. Larger clinical trials are now studying both drugs, both alone and/or in combination with other treatments. My task is and will continue to be using the same type of approach for attacking sarcomas and hopefully obtained the very promising results and long lasting responses observed with the use of immune checkpoint inhibitors in other types of cancer. Dr. Llosa is rated as an Advanced provider by MediFind in the treatment of Rhabdomyosarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Osteosarcoma, Malignant Peripheral Nerve Sheath Tumor, Rhabdomyosarcoma, and Bone Marrow Transplant.

Dr. Laura M. Fayad serves as the Chief of Musculoskeletal Imaging. She is a Professor in the Johns Hopkins University Department of Radiology and Radiological Science, Department of Oncology, and Department of Orthopaedic Surgery. Dr. Fayad is also the Director of the Translational Research Program in the Department of Radiology. Dr. Fayad earned a Bachelor of Science at the Massachusetts Institute of Technology, a Master of Science at Stanford University, and M.D. C.M. degrees at the McGill University Faculty of Medicine. She completed residency training at Columbia University and MRI Fellowship at Thomas Jefferson University. She specializes in diagnostic and interventional musculoskeletal radiology. In addition to routine sports medicine and spine applications, Dr. Fayad protocols and interprets specialized examinations in the areas of peripheral nerve imaging, tumor imaging, and rheumatology. Her primary area of research focuses on novel imaging techniques for musculoskeletal tumors, with her work including well over 100 publications that have been cited more than 1,500 times. Dr. Fayad is rated as an Advanced provider by MediFind in the treatment of Rhabdomyosarcoma. Her top areas of expertise are Schwannomatosis, Neurofibromatosis, Liposarcoma, and Neurofibromatosis Type 2 (NF2).

Debashish Bose is a Surgical Oncologist and a General Surgeon in Baltimore, Maryland. Dr. Bose is rated as an Experienced provider by MediFind in the treatment of Rhabdomyosarcoma. His top areas of expertise are Pancreatic Pseudocyst, Pancreatic Cancer, Familial Pancreatic Cancer, Pancreatectomy, and Small Bowel Resection. Dr. Bose is currently accepting new patients.

John Shern is a Hematologist and an Oncologist in Baltimore, Maryland. Dr. Shern is rated as a Distinguished provider by MediFind in the treatment of Rhabdomyosarcoma. His top areas of expertise are Rhabdomyosarcoma, Adult Soft Tissue Sarcoma, Ewing Sarcoma, and Osteosarcoma.

Paul Meltzer is a Hematologist and an Oncologist in Bethesda, Maryland. Dr. Meltzer is rated as a Distinguished provider by MediFind in the treatment of Rhabdomyosarcoma. His top areas of expertise are Osteosarcoma, Adult Soft Tissue Sarcoma, Ewing Sarcoma, Rhabdomyosarcoma, and Pancreaticoduodenectomy.

Dr. Cohen is Director of Pediatric Neuro-Oncology and Clinical Director of the Division of Pediatric Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He received his undergraduate degree at Brown University and earned his MD at the Upstate Medical University, in Syracuse, NY. He did his general Pediatric Residency and Chief Residency at the University of Colorado and completed his Pediatric Hematology/Oncology Fellowship at Johns Hopkins. He has served on the faculty since 1994. His research centers on clinical trials of novel therapeutics for children with brain tumors. Dr. Cohen is co-chair of the High-Grade Glioma committee for the Children's Oncology Group and in that capacity has a particular research interest in the development of therapeutics for the treatment of infiltrating gliomas. He serves on the scientific advisory board for a number of organizations including St. Baldricks and the Childhood Brain Tumor Foundation. He is on the editorial board for PDQ with responsibility for authorship of the pediatric CNS brain tumor summaries. The Pediatric Neuro-Oncology program conducts a broad range of research centered primarily around the development and testing of novel therapeutics for children with brain tumors. The multidisciplinary nature of this work translates into continual collaboration with specialists in pediatric neurosurgery, radiation oncology, neuropathology, neuroradiology, neurology, neuro-ophthalmology, neuropsychology, and other related disciplines. Dr. Cohen is rated as an Experienced provider by MediFind in the treatment of Rhabdomyosarcoma. His top areas of expertise are Glioma, Medulloblastoma, Brain Stem Cancer, Embryonal Tumor with Multilayered Rosettes, and Bone Marrow Aspiration.

Albert Aboulafia is an Orthopedics provider in Baltimore, Maryland. Dr. Aboulafia is rated as an Experienced provider by MediFind in the treatment of Rhabdomyosarcoma. His top areas of expertise are Bone Tumor, Myxoid Liposarcoma, Fibrosarcoma, Rhabdomyosarcoma Embryonal, and Hip Replacement.

Sahaja Acharya is the Director of Pediatric Radiation Oncology within the Department of Radiation Oncology and Molecular Radiation Sciences. She specializes in pediatric brain tumors, pediatric sarcomas, and adult sarcomas. She is also the Associate Director for the Radiation Oncology Residency Program. She leads the Pediatric Radiation Oncology program at the Johns Hopkins Hospital and treats patients at both Johns Hopkins Hospital and Sibley Memorial Hospital. She has extensive expertise in proton therapy, SBRT, pediatric malignancies, and adult sarcoma. She is the Principal Investigator on external grants from ASCO Conquer Cancer, the Department of Defense, and the Carson Leslie Foundation. She is also the Principal Investigator of phase II pediatric brain tumor clinical trials. She has been invited to participate in multiple national and international guideline committees and regularly lectures on pediatric malignancies and proton therapy. Dr. Acharya received her Bachelor's in Chemistry and Political Science from Stanford University and her medical degree from Saint Louis University. She completed radiation oncology residency at Washington University in St. Louis. Dr. Acharya is rated as an Experienced provider by MediFind in the treatment of Rhabdomyosarcoma. Her top areas of expertise are Brain Tumor, Glioma, Gliomatosis Cerebri, and Posterior Fossa Tumor.

William Burns, M.D., is an assistant professor of surgery at the Johns Hopkins University School of Medicine and a surgeon within the Division of Hepato-Pancreato-Biliary & Gastrointestinal Surgical Oncology at The Johns Hopkins Hospital. Prior to joining the faculty at Johns Hopkins, Dr. Burns served as an assistant professor of surgery at the University of Michigan, as well as an attending physician at the University of Michigan Health Systems and the VA Ann Arbor Healthcare System. Dr. Burns received his medical degree from Yale University School of Medicine and was awarded a research training fellowship by the Howard Hughes Medical Institute. He completed an internship and residency in general surgery at The Johns Hopkins Hospital followed by clinical fellowship training in complex general surgical oncology at The University of Texas MD Anderson Cancer Center. Additionally, he completed postgraduate research fellowships in the field of cancer immunotherapy and tumor immunology at the National Cancer Institute and the MD Anderson Cancer Center. Dr. Burns specializes in treating patients with tumors of the pancreas and gastrointestinal tract, sarcoma and melanoma. He is trained in traditional and minimally invasive surgical techniques. Furthermore, he works closely with colleagues in medical and radiation oncology to provide comprehensive cancer care. His research focuses on immune cell-tumor cell interactions to improve outcomes in patients with pancreatic cancer, cancer immunotherapy for solid tumors, the role of lymph node surgery in the treatment of cancer, and human biospecimen analysis to guide therapy in patients with cancer. He is a member of several professional societies, including the American College of Surgeons, Society of Surgical Oncology, Association of Academic Surgery, and Society of Immunotherapy for Cancer. Dr. Burns is rated as an Experienced provider by MediFind in the treatment of Rhabdomyosarcoma. His top areas of expertise are Neuroendocrine Tumor, Familial Pancreatic Cancer, Familial Colorectal Cancer, Small Bowel Resection, and Pancreatectomy.

Dr. Linda Chi Hang Chu is an Associate Professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science. Her clinical expertise includes body CT, MRI and US. Her research interests include abdominal imaging, cancer imaging, radiomics, and artificial intelligence. Dr. Chu graduated from the University of Toronto in 2003 and was awarded the Governor General's Silver Medal, the highest academic achievement from the undergraduate program. She earned her medical degree as a member of AOA and phi beta kappa from Johns Hopkins University in Baltimore, MD in 2007. She completed her Diagnostic Radiology residency and body MRI fellowship at Johns Hopkins Hospital. Dr. Chu joined the Johns Hopkins faculty in 2013. Dr. Chu is rated as an Experienced provider by MediFind in the treatment of Rhabdomyosarcoma. Her top areas of expertise are Pancreatic Ductal Adenocarcinoma, ALK-Positive Non-Small Cell Lung Cancer, Muscle Invasive Bladder Cancer, Pancreaticoduodenectomy, and Gallbladder Removal.

Dr. Cheng Ting Lin is an associate professor of radiology and radiological science at the Johns Hopkins University School of Medicine. His expertise is in diagnostic radiology with particular focus on chest and cardiac imaging. Dr. Cheng Ting Lin received his undergraduate degree from Boston University. He graduated from State University of New York at Stony Brook, where he also completed a radiology residency training program. Dr. Lin completed fellowship training in cardiothoracic imaging at University of Maryland Medical Center. His research interest includes lung cancer screening and diagnosis, chronic obstructive pulmonary disease, Interstitial lung disease, pulmonary embolism, and coronary artery disease. Dr. Lin is rated as an Experienced provider by MediFind in the treatment of Rhabdomyosarcoma. His top areas of expertise are Lung Nodules, Interstitial Lung Disease, Pulmonary Arteriovenous Fistula, Aortic Valve Replacement, and Transcatheter Aortic Valve Replacement (TAVR).

As an active participant in the medical community, Mohit Narang, M.D. has served as a primary investigator and research assistant on many trials. During Dr. Narang’s fellowship, he was honored with the invitation to attend the Masterclass in Clinical Oncology at Montecatini, Italy by the European School of Oncology. He holds professional memberships with the American Society of Clinical Oncology, American Society of Hematology, as well as the European Society of Medical Oncology. Learn more at marylandoncology.com. Dr. Narang is rated as an Experienced provider by MediFind in the treatment of Rhabdomyosarcoma. His top areas of expertise are Multiple Myeloma, Agranulocytosis, Paget Disease of the Breast, Thrombocytopenia, and Bone Marrow Transplant.

"Dr. Donna Magid, a Johns Hopkins Medicine Professor of Diagnostic Radiology, holds joint appointments in Orthopaedic Surgery and Functional Anatomy and Evolution. As Director of both the JHU SOM Horizontal Strand in Diagnostic Imaging, and Undergraduate Medical Education in Radiology, she develops and oversees educational programs and curriculae from Gross Anatomy through the Transition to Wards and clinical years to ensure a firm foundation in and comprehension of the intelligent, safe, effective use of imaging in medical practice and of appropriate consultation with Diagnostic Imagers. Dr. Magid is also recognized nationally and by the students for intense involvement with career mentoring and The Match, professionalism, and the 'Hidden Curriculum"", emphasizing precise appropriate use of medical English and the non-verbal aspects of professional demeanor and comportment. Her areas of clinical specialization include Musculoskeletal and Emergency Medicine radiography and joint procedures, including aspirations and pain-response studies, particularly in difficult patients who might otherwise require anesthesia for same. After receiving her BS summa cum laude in Psychology at Tufts University in Boston, she completed an M.Ed in Adolescent Psychology at Boston University. Her MD from Johns Hopkins School of Medicine was followed by one year out of the JHU system for internship at Harvard's Cambridge Hospital in Boston, after which she returned to JHM for Radiology Residency, Radiology Fellowship in CT and US , and subsequent faculty positions. Her career has been 'biphasic'; after a decade focused on nationally recognized Orthopaedic and Body CT research, she became heavily engaged with medical student and resident education and mentoring. After a decade as Co-Director of Resident Selection and Assistant Residency Program Director she shifted her focus, as she participated in the development and debut of JHU SOM's new curriculum, to the success of that curriculum and to the medical students. This focus and passion has been rewarded with multiple awards both at Hopkins and nationally, for teaching excellence and for published research in radiology education. Dr. Magid is participating in the writing and design of the ABR's new national mandated licensing exam for Diagnostic Radiology.". Dr. Magid is rated as an Experienced provider by MediFind in the treatment of Rhabdomyosarcoma. Her top areas of expertise are Scoliosis, Ollier Disease, Metachondromatosis, and Maffucci Syndrome.

Pamela Johnson is a Radiologist in Baltimore, Maryland. Dr. Johnson is rated as an Experienced provider by MediFind in the treatment of Rhabdomyosarcoma. Her top areas of expertise are Ampullary Cancer, Liposarcoma, Ureterocele, and Rhabdomyosarcoma Embryonal.

Brandi Page, M.D., is an assistant professor of radiation oncology and molecular sciences for Johns Hopkins Radiation Oncology Department at Suburban Hospital and a radiation oncologist at the Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital. Dr. Page has expertise in treating all types of cancer and, for the last several years, has become a highly sought-after specialist in the National Capitol Region (NCR-MD/DC/VA) for her expertise in treating head and neck and brain/central nervous system tumors. In Dr. Page's role with Johns Hopkins she has brought new complex radiotherapy services to the facility and facilitated the team building environment for collaborating practitioners and caregivers in the region. Dr. Page also serves on the Cancer Committee for Sibley and Suburban Hospitals for the American Cancer Society, which brings together multidisciplinary care providers to collaborate on initiatives for continued excellence. She is a teaching faculty member at the Johns Hopkins School of Medicine for medical students, residents and fellows, is the current director of radiation oncology fellowships, initiating and growing the first radiation oncology fellowship at the institution a year after the initiation of the proton center. Dr. Page earned her medical degree at Albany Medical College, completed residency in radiation oncology at the Huntsman Cancer Institute at the University of Utah, and fellowship in translational radiation oncology at Wake Forest University Medical Center, where she earned the Service Excellence in Patient Care Award. At Johns Hopkins she has won awards for clinical excellence nominated by peers many years in a row and a Faculty of the Year award for her teaching efforts. Dr. Page is a member of the American Society of Therapeutic Radiation Oncology, a diplomate of the American Board of Radiology, and a Fellow of the American College of Radiation Oncology. Dr. Page has served on the Board of Directors for Radiating Hope and currently serves on the Board of Directors for Courage Unmasked/911-4-HNC (a Head and Neck Cancer support organization). Dr. Page frequently serves as a sought after reviewer for peer reviewed articles and has served as the Continuing Medical Education Editor for the International Journal of Radiation Oncology Biology Physics (IJROBP). Dr. Page believes the best way to empower patients is with knowledge and partnership and she looks forward to partnering with patients in treating their condition, and helping them successfully get through their treatment and maximize opportunities for a happy healthy life after treatment. Make A Gift LinkedIn https://www.linkedin.com/in/brandi-page-968650b0. Dr. Page is rated as an Experienced provider by MediFind in the treatment of Rhabdomyosarcoma. Her top areas of expertise are Brain Tumor, Throat Cancer, Laryngeal Cancer, Glioma, and Gamma Knife Radiosurgery.

Dr. William H. Sharfman is an associate professor of oncology and dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include cutaneous oncology, dermatology and immunotherapy. He helped create the well-established Melanoma Program at the Johns Hopkins Kimmel Cancer Center in 1994. Dr. Sharfman serves as the director of cutaneous oncology and clinical co-director for oncology at the Johns Hopkins Melanoma Program. He earned his M.D. from the University of Toledo College of Medicine. He completed his residency at Cleveland Clinic and performed a fellowship in hematology and oncology at Cleveland Clinic. Dr. Sharfman's research interests include novel therapies for high risk and advanced melanoma patients. Dr. Sharfman is rated as an Experienced provider by MediFind in the treatment of Rhabdomyosarcoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Eccrine Porocarcinoma, and Pancreatic Cancer.